Drugs / Multivalent recombinant OspA Lyme Borreliosis Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01504347 | Mar → Sep 2011 | — | Baxalta now part of Shire | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Multivalent recombinant OspA Lyme Borreliosis Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01504347 ↗ |
| Known as | mv rOspA LB | “multivalent recombinant OspA Lyme Borreliosis (mv rOspA LB) Vaccine” NCT01504347 ↗ |
| Modality | Vaccine | “a novel multivalent OspA vaccine against Lyme borreliosis” PMID 25185574 ↗ Sep 2014 |
| Route | Intramuscular | “3 intramuscular injections” NCT01504347 ↗ |